Quantumzyme Corp. Reports No Revenue and Increased Losses for Three and Nine Months Ending April 30, 2025

Quantumzyme Corp., formerly known as Reliant Services, Inc., reported its financial results for the three and nine months ending April 30, 2025, revealing a continued lack of revenue generation. The company recorded no sales during these periods, maintaining a trend from the previous fiscal year. Operating expenses for the three months totaled $60,453, slightly up from $60,272 in the same quarter of 2024. For the nine-month period, operating expenses increased to $145,921 from $126,398 year-over-year, primarily due to higher professional fees.

The net loss for the three months ending April 30, 2025, was $65,763, compared to a loss of $63,862 in the same period last year. For the nine months, the net loss widened to $161,092 from $137,341. The increase in losses is attributed to rising operating expenses and interest costs associated with additional debt incurred during the reporting period. As of April 30, 2025, the company reported total current assets of $584 against total current liabilities of $403,125, resulting in a working capital deficit of $402,541.

In terms of strategic developments, Quantumzyme underwent a significant organizational change in February 2023 when Naveen Krishna Rao Kulkarni was appointed as the sole officer and director, succeeding Sandra Brossart. Following this leadership change, the company acquired assets from Quantumzyme Inc. related to the enzyme catalyst biotransformation sector, issuing 1.5 million shares of common stock in exchange. This acquisition is part of the company's strategy to pivot towards the biotransformation market.

Operationally, the company has not reported any significant customer growth or product adoption metrics, reflecting its ongoing challenges in establishing a market presence. The total number of common shares outstanding increased to 38,962,050 as of April 30, 2025, from 34,777,050 a year earlier, indicating some level of capital raising activity. However, the company continues to face substantial doubt regarding its ability to continue as a going concern, as it relies heavily on external funding sources to sustain operations.

Looking ahead, Quantumzyme's management has indicated that the company is focused on attracting funding through the sale of securities or private investments. However, there are no firm agreements in place, and the company acknowledges the risks associated with its financial condition. The inability to secure necessary financing could severely limit its operational capabilities and growth potential, potentially leading to a suspension of business activities.